Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Douglas Mental Health Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest de l'Île de Montréal, Montreal, Canada.
Alzheimers Dement. 2023 Dec;19(12):5343-5354. doi: 10.1002/alz.13119. Epub 2023 May 15.
Fluid biomarkers capable of specifically tracking tau tangle pathology in vivo are greatly needed.
We measured cerebrospinal fluid (CSF) and plasma concentrations of N-terminal tau fragments (NTA-tau), using a novel immunoassay (NTA) in the TRIAD cohort, consisting of 272 individuals assessed with amyloid beta (Aβ) positron emission tomography (PET), tau PET, magnetic resonance imaging (MRI) and cognitive assessments.
CSF and plasma NTA-tau concentrations were specifically increased in cognitively impaired Aβ-positive groups. CSF and plasma NTA-tau concentrations displayed stronger correlations with tau PET than with Aβ PET and MRI, both in global uptake and at the voxel level. Regression models demonstrated that both CSF and plasma NTA-tau are preferentially associated with tau pathology. Moreover, plasma NTA-tau was associated with longitudinal tau PET accumulation across the aging and Alzheimer's disease (AD) spectrum.
NTA-tau is a biomarker closely associated with in vivo tau deposition in the AD continuum and has potential as a tau tangle biomarker in clinical settings and trials.
An assay for detecting N-terminal tau fragments (NTA-tau) in plasma and CSF was evaluated. NTA-tau is more closely associated with tau PET than amyloid PET or neurodegeneration. NTA-tau can successfully track in vivo tau deposition across the AD continuum. Plasma NTA-tau increased over time only in cognitively impaired amyloid-β positive individuals.
目前非常需要能够特异性追踪体内 tau 缠结病理的液体生物标志物。
我们在 TRIAD 队列中使用新型免疫测定法（NTA）测量了 272 名个体的脑脊液（CSF）和血浆中 N 端 tau 片段（NTA-tau）的浓度，这些个体接受了淀粉样蛋白β（Aβ）正电子发射断层扫描（PET）、tau PET、磁共振成像（MRI）和认知评估。
在认知障碍的 Aβ 阳性组中，CSF 和血浆 NTA-tau 浓度特异性升高。CSF 和血浆 NTA-tau 浓度与 tau PET 的相关性强于与 Aβ PET 和 MRI 的相关性，无论是在总体摄取还是在体素水平上。回归模型表明，CSF 和血浆 NTA-tau 均与 tau 病理密切相关。此外，血浆 NTA-tau 与 AD 连续谱中 tau PET 的纵向积累相关。
NTA-tau 是与 AD 连续谱中体内 tau 沉积密切相关的生物标志物，具有在临床环境和试验中作为 tau 缠结生物标志物的潜力。
评估了用于检测血浆和 CSF 中 N 端 tau 片段（NTA-tau）的测定法。NTA-tau 与 tau PET 的相关性强于与淀粉样蛋白 PET 或神经退行性变的相关性。NTA-tau 可以成功地在 AD 连续谱中追踪体内 tau 沉积。只有在认知障碍的 Aβ 阳性个体中，血浆 NTA-tau 才会随着时间的推移而增加。
